Neuberger Berman Group’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $67.3M | Buy |
3,887,179
+204,895
| +6% | +$2.81M | 0.04% | 439 |
|
|
2026
Q1 | $45.7M | Buy |
3,682,284
+26,893
| +0.7% | +$361K | 0.03% | 495 |
|
|
2025
Q4 | $46.1M | Sell |
3,655,391
-60,684
| -2% | -$694K | 0.03% | 485 |
|
|
2025
Q3 | $37.2M | Sell |
3,716,075
-7,253
| -0.2% | -$65.1K | 0.03% | 527 |
|
|
2025
Q2 | $30.1M | Sell |
3,723,328
-11,755
| -0.3% | -$88.6K | 0.02% | 555 |
|
|
2025
Q1 | $31.4M | Sell |
3,735,083
-27,664
| -0.7% | -$231K | 0.03% | 525 |
|
|
2024
Q4 | $29.8M | Sell |
3,762,747
-24,918
| -0.7% | -$209K | 0.02% | 564 |
|
|
2024
Q3 | $31.5M | Buy |
3,787,665
+219,312
| +6% | +$1.71M | 0.02% | 540 |
|
|
2024
Q2 | $22.7M | Sell |
3,568,353
-352,622
| -9% | -$2.24M | 0.02% | 609 |
|
|
2024
Q1 | $23.8M | Buy |
3,920,975
+179,968
| +5% | +$1.01M | 0.02% | 609 |
|
|
2023
Q4 | $22.7M | Sell |
3,741,007
-84,603
| -2% | -$377K | 0.02% | 592 |
|
|
2023
Q3 | $16.2M | Buy |
3,825,610
+77,671
| +2% | +$290K | 0.01% | 640 |
|
|
2023
Q2 | $11.5M | Buy |
3,747,939
+65,312
| +2% | +$139K | 0.01% | 725 |
|
|
2023
Q1 | $5.11M | Buy |
3,682,627
+192,972
| +6% | +$384K | ﹤0.01% | 873 |
|
|
2022
Q4 | $6.94M | Buy |
3,489,655
+1,736
| +0% | +$3.89K | 0.01% | 812 |
|
|
2022
Q3 | $7.06M | Buy |
3,487,919
+260,027
| +8% | +$729K | 0.01% | 807 |
|
|
2022
Q2 | $10.3M | Buy |
3,227,892
+29,524
| +0.9% | +$107K | 0.01% | 743 |
|
|
2022
Q1 | $13.3M | Sell |
3,198,368
-70,180
| -2% | -$311K | 0.01% | 756 |
|
|
2021
Q4 | $15.6M | Sell |
3,268,548
-43,626
| -1% | -$217K | 0.01% | 744 |
|
|
2021
Q3 | $17.5M | Sell |
3,312,174
-53,907
| -2% | -$271K | 0.02% | 717 |
|
|
2021
Q2 | $17.1M | Sell |
3,366,081
-68,185
| -2% | -$388K | 0.02% | 736 |
|
|
2021
Q1 | $23M | Sell |
3,434,266
-185,556
| -5% | -$1.03M | 0.02% | 648 |
|
|
2020
Q4 | $16.5M | Sell |
3,619,822
-65,655
| -2% | -$291K | 0.02% | 695 |
|
|
2020
Q3 | $14.3M | Sell |
3,685,477
-53,707
| -1% | -$230K | 0.02% | 656 |
|
|
2020
Q2 | $17.8M | Sell |
3,739,184
-90,902
| -2% | -$374K | 0.02% | 593 |
|
|
2020
Q1 | $13.3M | Buy |
3,830,086
+312,170
| +9% | +$1.32M | 0.02% | 593 |
|
|
2019
Q4 | $16.9M | Sell |
3,517,916
-49,283
| -1% | -$171K | 0.02% | 635 |
|
|
2019
Q3 | $10.4M | Buy |
3,567,199
+982,549
| +38% | +$3.43M | 0.01% | 710 |
|
|
2019
Q2 | $18.5M | Buy |
2,584,650
+874,651
| +51% | +$8.94M | 0.02% | 618 |
|
|
2019
Q1 | $24.2M | Buy |
1,709,999
+28,747
| +2% | +$380K | 0.03% | 556 |
|
|
2018
Q4 | $22.8M | Sell |
1,681,252
-38,546
| -2% | -$695K | 0.03% | 525 |
|
|
2018
Q3 | $38.2M | Sell |
1,719,798
-56,095
| -3% | -$1.18M | 0.04% | 461 |
|
|
2018
Q2 | $29.1M | Buy |
+1,775,893
| New | +$31.2M | 0.03% | 543 |
|
Other funds holding AMRX
TGA
RCMNY
Neuberger Berman Group's AMRX Position: Q2 2026 in Review
Neuberger Berman Group increased its Amneal Pharmaceuticals (AMRX) stake by 5.6% in Q2 2026, buying an estimated $2.81M and bringing the position to 3,887,179 shares worth $67.3M. The position accounts for 0.04% of the portfolio, ranked #439.
Neuberger Berman Group first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Neuberger Berman Group held 3,887,179 shares of Amneal Pharmaceuticals worth $67.3M as of Q2 2026.
- Neuberger Berman Group bought 204,895 Amneal Pharmaceuticals shares in Q2 2026, an estimated $2.81M.
- Amneal Pharmaceuticals made up 0.04% of Neuberger Berman Group's portfolio in Q2 2026, its #439 holding.
- Neuberger Berman Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.